HC Wainwright Analysts Raise Earnings Estimates for GRI Bio

GRI Bio, Inc. (NASDAQ:GRI) – Investment analysts at HC Wainwright upped their Q3 2026 EPS estimates for GRI Bio in a research report issued to clients and investors on Thursday, September 10th. HC Wainwright analyst M. Keller now forecasts that the company will earn ($0.75) per share for the quarter, up from their previous forecast of ($0.95). HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for GRI Bio’s current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for GRI Bio’s Q4 2026 earnings at ($0.74) EPS, FY2026 earnings at ($3.36) EPS, FY2027 earnings at ($0.21) EPS and FY2028 earnings at ($0.17) EPS.

GRI Bio (NASDAQ:GRI) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.19) by $0.28.

A number of other equities analysts have also recently weighed in on GRI. Ascendiant Capital Markets cut their price target on GRI Bio from $40.00 to $32.00 and set a “buy” rating for the company in a report on Monday, June 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of GRI Bio in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $21.00.

GRI Bio Stock Performance

Shares of NASDAQ:GRI opened at $1.89 on Monday. The business’s fifty day moving average price is $1.76 and its two-hundred day moving average price is $2.09. The stock has a market cap of $4.14 million, a PE ratio of -0.05 and a beta of -1.24. GRI Bio has a one year low of $1.36 and a one year high of $64.12.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.